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The vertebrate Sox9 transcription factor directs the development of neural crest, otic placodes, cartilage and bone. In zebrafish, there are two
Sox9 orthologs, Sox9a and Sox9b, which together perform the functions of the single-copy tetrapod Sox9. In a large-scale genetic screen, we have
identified a novel zebrafish mutant that strongly resembles the Sox9a/Sox9b double mutant phenotype. We show that this mutation disrupts the
zebrafish Trap230/Med12 ortholog, a member of the Mediator complex. Mediator is a coactivator complex transducing the interaction of DNA-
binding transcription factors with RNA polymerase II, and our results reveal a critical function of the Trap230 subunit as a coactivator for Sox9.
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The precise control of transcription is of central importance
during the development of multicellular animals, as it leads to
cell-type-specific gene expression required for differentiation.
Sox proteins are a large family of transcription factors
implicated in the control of a variety of developmental
processes. They are characterized by the presence of an HMG
box, a sequence-specific DNA-binding domain, and by their
homology to SRY, the mammalian testis-determining factor
(reviewed in Pevny and Lovell-Badge, 1997; Wegner, 1999).
One member of the Sox family, Sox9, is known to function
in the development of neural crest, epithelial placodes, cartilage
and bone. Sox9 is sufficient to induce a number of neural crest-
like behaviors in neural tube cells (Cheung and Briscoe, 2003),
and tissue-specific inactivation of Sox9 function in neural crest
leads to loss of cranial and trunk neural crest derivatives in
Xenopus and mice (Spokony et al., 2002; Mori-Akiyama et al.,
2003; Cheung et al., 2005). At later stages, Sox9 is required in
mesenchymal condensations for the morphogenesis and⁎ Corresponding author. Fax: +49 6221 387 166.
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et al., 2002; Yan et al., 2002). During chondrogenesis, Sox9 is
coexpressed with type-II collagen a1 (Col2a1), which encodes
the major cartilage matrix protein, and Sox9 has been shown to
directly activate transcription of col2a1 by binding to a
chondrocyte-specific enhancer present in its first intron (Bell
et al., 1997; Lefebvre et al., 1997; Ng et al., 1997; Zhou et al.,
1998). In contrast to mice, where defects are only observed in
homozygous Sox9 mutants, in humans, heterozygous mutations
in Sox9 are associated with campomelic dysplasia (CD), which
is characterized by skeletal malformations and XY sex reversal
(Houston et al., 1983; Wagner et al., 1994).
Sox9 activity is also crucial for inner ear development, as the
otic placode fails to form in the absence of Sox9 activity,
indicating that Sox9 acts at a very early step in the induction of
this placode (Saint-Germain et al., 2004; Yan et al., 2005).
Consistent with this proposal, Sox9 is expressed in the otic
placode at very early stages, and Pax8 and Tbx2, which are also
expressed in the early otic placode, fail to be activated in the
absence of Sox9.
Due to the additional genome duplication at the base of the
teleost radiation, zebrafish have two Sox9 coorthologs: Sox9a
and Sox9b. Functional analysis indicates that these two Sox9
orthologs have partitioned the various functions of the
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original functions (Yan et al., 2002, 2005). This subfunctio-
nalization appears to be achieved at the level of transcription,
as Sox9a and Sox9b are expressed in largely complementary
domains that together approximate the expression of Sox9 in
tetrapods.
The Mediator complex is a key coactivator acting as a
bridge between DNA-binding transcription factors and RNA
polymerase II (pol II), thus conveying regulatory information
from enhancer elements to the basal transcription machinery
(reviewed in Björklund and Gustafsson, 2005; Kim and Lis,
2005; Malik and Roeder, 2005). It consists of up to 30
subunits that are largely conserved from yeast to mammals.
While some Mediator subunits appear to be universally
required for the transcription of all genes, a number of
subunits are dedicated to the regulation of specific genes. For
example, in Drosophila, mutations in Trap80 and Med6 are
cell-lethal, suggesting these subunits are essential for general
functions of the Mediator complex (Boube et al., 2000; Gim
et al., 2001). Mutations in Drosophila Trap230/Med12 and
Trap240/Med13, on the other hand, are cell-viable and show
deregulation of specific genes during imaginal disc develop-
ment (Janody et al., 2003). In C. elegans, Trap230/Med12
and Trap240/Med13 are specifically required for the
regulation of genes controlling asymmetric cell division
(Yoda et al., 2005).
To date, little genetic evidence is available on the vertebrate
Mediator complex. Mouse Med1 mutants are viable, but
fibroblasts derived from Med1 mutants fail to differentiate
into adipocytes in response to PPARγ (Ito et al., 2000; Ge et al.,
2002), and knock down of Med15 in Xenopus leads to defects in
activin and nodal signaling through Smad transcription factors
(Kato et al., 2002).
Here, we characterize a novel zebrafish mutant strongly
resembling the Sox9a/Sox9b compound phenotype and show
that this mutation disrupts zebrafish Trap230. Inactivation of
Trap230 leads to dramatically reduced differentiation of bone
and cartilage, reduced iridophores and the absence of otic
placodes. All these phenotypes are observed in Sox9a/Sox9b
double mutants. Furthermore, injection of Sox9b mRNA fails to
activate target genes in the absence of Trap230, indicating that
Trap230 is required for Sox9 activity. Interestingly, substitution
of the Sox9b transactivation domain with a VP16 transactiva-
tion domain renders Sox9b independent of Trap230, indicating
that Trap230 acts as a coactivator rather than corepressor in this
context. Finally, we show that Trap230 is also required during
pectoral fin development downstream of Tbx5 and upstream of
Fgf24 and therefore also participates in Sox9-independent
transcriptional regulation.
Materials and methods
Fish stocks
The trapped allele used was tpdt25870. Embryos were cultured in E3medium,
with or without the addition of 0.003% 1-phenyl-2-thiourea (PTU, Sigma) to
inhibit pigmentation. Embryos were staged according to hours post-fertilization
(hpf; Westerfield, 1995).Linkage analysis and genetic mapping
For fine mapping of tpd, SSLPs were generated using the Sanger genome
database. The closest SSLP marker to the tpd mutation, P1, uses the primer pair
GCATCCACCCAAACATGAGG (forward) and GCAGTGCGATTGATGT-
TGGG (reverse), at a distance of <0.08 cM south of the mutation.
Microinjection of morpholino oligonucleotides and mRNA
Trap230 splice morpholino oligonucleotide (MO) was purchased from
GeneTools LLC. The MO, designed to target the exon 26–intron 26 splice
junction, has the sequence CAGATCCTCTAAAAATCATCACCTG. A MO
stock solution was formed by dilution in water and was stored at −20°C prior to
use. Embryos were injected at the single cell stage with 0.25 mM MO.
The N-terminal portion of Sox9b (comprising the HMG-box DNA-binding
domain) was fused to the VP16 transactivation domain (amino acids 401–478 of
the VP16 protein from human Herpes simplex virus type I). The 5′UTR and the
N-terminal coding region of Sox9b was PCR amplified and cloned into the
BamHI site of a pCS2 + VP16 vector.
prdm1-mRNA, Sox9b-mRNA and Sox9b-VP16-mRNA were synthesized
using the SP6 mMessage mMachine kit (Ambion) from a full-length clone
obtained at RZPD and injected at single-cell-stage with a concentration of
90 ng/μl.
Histochemical methods
In situ hybridization and immunohistochemistry were performed as
previously described (Hauptmann and Gerster, 1994, Macdonald et al., 1994).
The trap230 in situ probe was synthesized using the following primers: forward
primer GGTGGGTGGGATGTTTGAC, reverse primer TTCACAGAA-
CAACGCCAGTATG. All other in situ probes have been previously described.
For immunohistochemistry, mouse anti-Hu was used (Marusich et al., 1994).
Alcian blue staining of cartilage was performed as described in Grandel and
Schulte-Merker (1998). Histological sections were obtained by staining
cryosections with methylene blue (Humphrey and Pittman, 1974). TUNEL
staining was performed using the in situ cell death TMR red kit (Roche).
Results
Isolation of a mutation in zebrafish Trap230/Med12
In a large-scale genetic screen to identify genes required for
zebrafish embryonic development (Habeck et al., 2002), we
isolated a novel mutant, trapped (tpd), with defects in
craniofacial development, pigmentation, ear development and
pectoral fin outgrowth (Figs. 2A, B, D, E; data not shown). In
addition, tpd mutants have a heart edema and a curly-down
body axis (Fig. 2B).
In order to identify the molecular nature of tpd, we used
bulked segregant analysis to map it to linkage group 14 (Fig.
1A), between markers Z53264 (0.35 cM away) and Z11725
(0.65 cM away). By making use of the zebrafish genomic
sequence (http://vega.sanger.ac.uk/Danio_rerio/) available for
this interval, we then constructed new SSLP markers based on
CA repeats. For one of these markers, termed P1, we failed to
obtain any recombinants with tpd, indicating that it must lie
very close to the tpd mutation (Fig. 1A). We considered several
candidate genes in the region close to P1 and compared their
sequence between wild type and tpd mutants. For one of these,
the Trap230/Med12 gene (which we refer to as Trap230
hereafter), we found a difference in cDNA sequence between
wild types and mutants (Fig. 1B). Since we found two different
Fig. 2. The overall Trap230 loss-of-function phenotype. (A, D, G, H) WT, (B, E) tpd, (C) Trap230 morpholino-injected embryos. (A–E) Embryos at 3 dpf. (D, E)
Methylene blue-stained transverse sections at the level of the pectoral fin buds (arrows and asterisks). (F) Trap230 MO-injected embryos lack the RT-PCR product
amplified from exons 26 and 27, since intron 26 fails to be spliced out. (G, H) trap230mRNA expression. (G) Four-cell stage, animal pole to the top. (H) Three-somite
stage, lateral view, dorsal to the top, anterior to the left. MO: Trap230 morpholino injected.
Fig. 1. Molecular characterization of the tpd locus. (A) tpd maps to linkage group 14 (LG 14), between markers Z53264 and Z11725, close to marker P1. (B) The tpd
mutation (marked in red) causes an alteration of the splice donor site of intron 12. Two defectively spliced transcripts are generated as a result of this mutation. cDNA1
is spliced at a cryptic splice site (shaded in yellow) within exon 12. This leads to a frame shift and a stop codon after 93 amino acids. cDNA2 contains unspliced intron
12, leading to a stop codon after 4 amino acids. (C) Restriction enzyme Est1 cuts genomic tpd but not WT DNA due to the point mutation in its recognition site. het:
DNA from a heterozygous embryo. L: leucine-rich domain; LS leucine-and-serine-rich domain; PQL: proline-, glutamine-, and leucine-rich domain; OPA: glutamine-
rich domain.
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aberrant splicing at the exon 12/intron 12 junction, we also
sequenced the genomic locus of tpdt25870. We find the splice
donor site of intron 12 altered from CAgtgag to CAgcgag
(capitalized nucleotides belong to exon 12; Fig. 1B). This
mutation changes the highly conserved GU found at the intronic
5′ splice site to GC and results in two types of aberrant splicing
in tpdt25870 mutants: In type 1 cDNAs, a cryptic splice site
(CTgtgct) located 7 bases 5′ of the correct splice site is used,
resulting in a frame shift and a stop codon 90 amino acids
downstream of this point (Fig. 1B). In type 2 cDNAs, intron 12
fails to be spliced at all, and its translation generates a stop
codon 5 amino acids downstream of this point (Fig. 1B). In both
cases, the tpdt25870 mutation results in a severely truncated
Trap230 protein, in which more than half the C-terminus is
missing, corresponding to a loss of most functional domains of
the protein (Fig. 1B). Nevertheless, this tpd allele may be
hypomorphic, as it shows some variability in its phenotype (see
Figs. 3A–C below; data not shown). This could be due to a
small percentage of correctly spliced transcripts. The trap230
transcript is expressed ubiquitously throughout the embryo at all
stages, and is also deposited maternally (Figs. 2G, H; data not
shown).
To further investigate the possibility that tpd disrupts
Trap230, we designed a morpholino oligonucleotide to block
splicing of the trap230 transcript at the exon 26–intron 26
splice junction (Fig. 2F). We find that injection of this
morpholino into fertilized one-cell stage zebrafish embryos
generates a phenocopy of tpd mutants, including absence of
pectoral fins, identical ear, pigmentation and craniofacial
defects, and a curly-down body axis (Fig. 2C). Although the
tpd mutation and the morpholino oligonucleotide target
different splice sites, both lead to the absence of the C-terminal
PQL domain, which is crucial for Trap230 function, and hence,
their phenotype is almost indistinguishable.
Taken together, these data show that the tpd phenotype is due
to disruption of zebrafish Trap230 function.
The Trap230 phenotype resembles loss of Sox9 activity in many
different tissues
Since several of the phenotypes we observed in tpd mutants
affect cell types known to depend on Sox9 function, we
systematically compared the characterized phenotypes of
zebrafish Sox9a/Sox9b single and double mutants (Yan et al.,
2005) to the phenotypes present in tpd embryos. In Sox9a/
Sox9b double mutants, the ear fails to form, while it is only
partially reduced in Sox9a or Sox9b single mutants. We find the
ear is variably reduced in tpd mutants (Figs. 3A–C), similar to
Sox9bmutants. In Trap230 morphants, however, the ear is either
partially reduced or completely absent (Figs. 3D, E), similar to
Sox9a/Sox9b double mutants, suggesting the morpholino knock
down leads to a stronger reduction of Trap230 function than the
tpd mutation, and further indicating that tpdt25870 is a
hypomorphic mutation.
In Sox9b or Sox9a/Sox9b double mutants, there is an absence
of iridophores, which are neural crest-derived pigment cells thatcan be detected as bright, shiny cells in dark field microscopy
(Fig. 3F). As in Sox9b single mutants or Sox9a/Sox9b double
mutants, we detect no iridophores in tpd mutants (Figs. 3F, G).
Melanocytes, on the other hand, are present in Sox9a/Sox9b
mutants but are larger than in wild types, due to dispersed
melanosomes even in bright light (Yan et al., 2005).
Melanocytes are similarly enlarged in tpd mutants and in
Trap230 morphants (Figs. 3J–L).
Sox9b mutants fail to straighten the body axis, resulting
in a curly-down tail, probably due to Sox9b function in the
notochord (Yan et al., 2005). We observe a similar curly-
down body axis in tpd mutants and in Trap230 morphants
(Figs. 2B, C).
Taken together, these results show that Trap230 loss-of-
function strongly resembles zebrafish Sox9a/Sox9b mutants
with respect to ear, pigmentation, and body axis development.
Trap230 is required for Sox9-dependent neural crest fates and
craniofacial cartilage formation
To further investigate the role of Trap230 in Sox9 signaling,
we examined the expression of col2a1, which is expressed
during the differentiation of craniofacial cartilage elements and
is a direct target of Sox9 binding and activation (Bell et al.,
1997; Lefebvre et al., 1997; Ng et al., 1997; Zhou et al., 1998).
In Sox9a/Sox9b double mutants, col2a1 expression is strongly
reduced, although not completely absent, in the pharyngeal
arches, the eye capsule and the otic vesicle (Yan et al., 2005).
We find a similar reduction of col2a1 in these expression
domains in tpd embryos (Figs. 4A, B).
While either Sox9a or Sox9b single mutants show partial
absence of craniofacial cartilages, the Sox9a/Sox9b double
mutant animals lack all traces of pharyngeal cartilages and the
neurocranium (Yan et al., 2005). Likewise, tpd mutants have a
complete absence of both the pharyngeal cartilages and the
neurocranium, as well as total absence of the pectoral fin
skeleton (Figs. 4C, D).
In Sox9b and Sox9a/Sox9b double mutants, dlx2a expression
is slightly reduced, with the strongest reduction in the posterior
branchial arches (Yan et al., 2005). In tpd mutants, there is a
similar reduction of dlx2a, which is also more pronounced in the
posterior arches (Figs. 4C, D).
Sox10 is expressed in a subpopulation of trunk neural crest
cells migrating in the medial pathway. In Sox9b and Sox9a/
Sox9b double mutants, Sox10-expressing neural crest cells fail
to migrate as far ventrally as normally observed (Yan et al.,
2005). We observed a similar phenotype in the trunk of tpd
embryos (Figs. 4G, H), indicating that trap230 and Sox9b are
required for migration of the same population of Sox10-
expressing neural crest cells.
An important derivative of trunk neural crest are the neurons
and glia found in dorsal root ganglia (DRG), and in mouse Sox9
mutants, these cell types are strongly reduced (Cheung et al.,
2005). Similarly, we failed to detect Hu-positive DRG neurons
in Trap230 morphants (Figs. 4I, J). Both in mouse Sox9 mutants
and in zebrafish Sox9bmutants, neural crest cells are formed but
then undergo apoptosis (Cheung et al., 2005; Yan et al., 2005).
Fig. 3. Ear and pigmentation phenotypes in tpdmutants and Trap230 morphants. (A–G, J–L) Embryos at 4 dpf. (H, I) Embryos at 28 hpf. (A–E) Ear phenotypes; note
partial reduction in tpd mutants (C), and complete absence in some Trap230 morphants (D). (F, G) Dark field microscopy, revealing iridophores (bright shiny cells),
present in WT (F), but not in tpdmutants (G). (H, I) TUNEL staining, lateral view of embryos. (J–L) Trunk melanocytes (dark cells, arrows). (A, F, H, J) WT; (B, C, G,
I, K) tpd mutants; (D, E, L) Trap230 MO-injected embryos.
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labeling in tpd mutants (Figs. 3H, I).
Altogether, these results show that Trap230 activity is crucial
for Sox9-dependent neural crest development and cartilage
differentiation, and that many of the defects found in tpd
embryos are identical to those found in Sox9 mutants.
Trap230 is required as a coactivator for Sox9
The similarity of the tpd phenotype to that of Sox9a/Sox9b
mutants could potentially reflect two different modes ofFig. 4. Neural crest and craniofacial phenotypes of tpd mutants. (A, C, E, G) WT; (B
view. (C, D) Expression of dlx2a in the pharyngeal arches at 24 hpf, dorsal view. (E, F
the trunk region of wild type (G) and tpdmutants (H). Note the absence of ventrally m
3 dpf, lateral view of the trunk. Arrows indicate the position of DRGs. Note the absregulatory interaction between Trap230 and Sox9. Since
Trap230 is involved in transcriptional regulation, it might be
required for expression of Sox9a and Sox9b. Alternatively, it
might be required for the transcriptional regulation of Sox9
targets.
To distinguish between these possibilities, we first examined
the expression of Sox9a and Sox9b mRNA in the absence of
Trap230 activity. We find that Sox9a expression is largely
normal in tpd mutants compared to wild type siblings, both at
10 hpf and at 24 hpf (Figs. 5A–D). The exceptions to this are
the pectoral fin buds, in which Sox9a expression fails to be, D, F, H) tpd mutants. (A, B) Expression of col2a1 in the head at 68 hpf, lateral
) Alcian blue-stained cartilages at 5 dpf, ventral view. (G, H) Sox10 Expression in
igrating Sox10-expressing cells in tpdmutants. (I, J) Anti-Hu immunostaining at
ence of DRGs in tpd mutants.
Fig. 5. Sox9a and Sox9b expression in tpdmutants. (A, C, E, G) WT; (B, D) tpdmutants; (F, H) Trap230 MO-injected embryos. (A, B) Embryos at 10 hpf, animal pole
to the top. (E, F) Embryos at 3-somite stage, dorsal view, anterior to the left. (C, D, G, H) Embryos at 24 hpf, lateral view, anterior to the left. (A–D) Expression of
Sox9a. (E–H) Expression of Sox9b. Note that Sox9a and Sox9b expression is only weakly reduced in the absence of Trap230 (B, F).
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in which Sox9a expression is activated, but at reduced levels
compared to wild type siblings (Figs. 7A, B). Sox9b expressionFig. 6. Trap230 is required as a coactivator for Sox9. (A, C, E, G, I, K, M, O) WT e
dorsal view, anterior to the left. (A–D) foxd3 expression. (E–H, K, L) snai1b Express
with Sox9b mRNA; (D, H) tpd mutant injected with Sox9b mRNA. (K) WT embry
mRNA. (O) WT embryo injected with prdm1 mRNA. (P) tpd mutant injected withis also largely normal in Trap230 morphants (Figs. 5E–H),
although there is a weak reduction in the neural crest region at 3
somites (Figs. 5E, F). This reduction of Sox9b in neural crest ofmbryos. (B, D, F, H, J, L, N, P) tpd mutants. Embryos are at the 3-somite stage,
ion. (I, J) Sox10 expression. (M–P) six3 expression. (C, G) WT embryo injected
o injected with Sox9b-VP16 mRNA; (L) tpd mutant injected with Sox9b-VP16
prdm1 mRNA.
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Sox9 on its own expression (Yan et al., 2005).
While the weak reduction of Sox9a or Sox9b expression may
contribute to the tpd phenotype, it is not sufficient to explain it
entirely, since robust expression of these genes is present in
tissues strongly affected by the tpd mutation. We therefore
examined the ability of Sox9b mRNA to trigger downstream
target gene activation in the absence of Trap230 activity. Since
expression of foxd3, snai1b and Sox10 is up-regulated in wild
type embryos injected with Sox9b mRNA (Yan et al., 2005), we
injected Sox9b mRNA into one-cell stage wild type and tpd
embryos, to compare the effect of Sox9b in the presence or
absence of Trap230 activity. While Sox9b mRNA injection
leads to strong up-regulation of foxd3 and snai1b expression in
wild type embryos (Figs. 6C, G), we detect only very weak up-
regulation in tpd embryos (Figs. 6D, H). We obtained similar
results with Sox10, which also fails to respond to Sox9b in the
absence of Trap230 (data not shown).
Our results raise the possibility that Trap230 acts as a
coactivator required for expression of Sox9 target genes. To
further test this hypothesis, we constructed a fusion protein in
which the Sox9b transactivation domain was replaced by the
VP16 activator domain. We injected mRNA encoding this
construct into wild type and tpd embryos and found that snai1b
expression was equally up-regulated in both cases (Figs. 6K, L),
indicating that Sox9b-VP16 activates snai1b independently of
Trap230. The observation that Sox9b mRNA overexpression is
phenocopied by a VP16 activator fusion protein shows that
Sox9b acts as a transcriptional activator in this context, and that
Trap230 is therefore required as a coactivator for Sox9.
As a control, we tested the requirement of Trap230 for
activity of Prdm1, an unrelated transcription factor. Over-
expression of prdm1 mRNA leads to downregulation of six3
expression in the eye field (Wilm and Solnica-Krezel, 2005).
Overexpression of prdm1 mRNA in both wild type and tpd
embryos was found to similarly reduce expression of six3 in the
eyefield (Figs. 6O, P), indicating that Trap230 is not required
for Prdm1 activity.
Taken together, these results show that Trap230 acts as a
coactivator for Sox9 and is required for transcription of Sox9
target genes.
The role of Trap230 in Sox9-dependent ear development
Sox9 has been shown to be one of the earliest genes
expressed in the otic placode, and knock down of Sox9 activity
in Xenopus leads to complete absence of the ear (Saint-Germain
et al., 2004). pax8 is also expressed very early in the otic
placode, and pax8 expression fails to be activated following
Sox9 knock down. Similarly, we detect no pax8 expression in
the otic placode of Trap230 morphants (Figs. 7E, F), even
though Sox9a and Sox9b expression is present in the otic
placode of these morphants, although at partially reduced levels
(Figs. 7A–D). In addition, there is also a strong reduction of
pax8 expression in the pronephric anlage of Trap230 morphants
(Figs. 7E, F), indicating that Trap230 is also required for Sox9-
independent effects during embryogenesis. In the majority ofTrap230 morphants, there is a partial recovery of ear
development later on, leading to a reduced number of cells
expressing pax2.1 compared to wild-type siblings at 24 hpf
(Figs. 7G, H). This partial recovery of morphants is likely due
to incomplete blockage of trap230 splicing, since a small
number of morphants do not have any signs of ear development
(Fig. 3D).
These results show that Trap230 is required for Sox9-
dependent activation of pax8 in the ear and for Sox9-dependent
ear development and further indicate that Trap230 is required
for Sox9 activity.
A Sox9-independent role of Trap230 in forelimb development
Since tpd mutants show a complete absence of pectoral fins
in the most strongly affected mutants (Figs. 2D, E), we were
interested to determine how Trap230 fits into the cascade of
genes involved in limb induction. It is well established that both
tbx5 mutants (Ahn et al., 2002; Garrity et al., 2002; Ng et al.,
2002) and fgf24 mutants (Fischer et al., 2003) show a similar
absence of pectoral fins. We therefore examined the expression
of these two genes, as well as other genes known to be regulated
by them, in tpd mutants.
We find that tbx5 expression is activated in tpd mutants, but
tbx5-expressing cells fail to congregate towards the fin bud and
stay dispersed in the lateral plate mesoderm (Figs. 8B, F). fgf24
expression, by contrast, fails to be activated at all in tpdmutants
(Figs. 8C, G). Consistent with this result, Fgf24-dependent
expression of dlx2a in the fin bud ectoderm and of shh in the fin
bud mesenchyme (Fischer et al., 2003) are not detectable in tpd
mutants (Figs. 8I, M, J, N). We also observed that activation of
erm1, pea3 and msx-c is strongly reduced in the pectoral fin
buds of tpd mutants (Figs. 8D, H, K, O, L, P). Since these three
genes are activated in the absence of Fgf24 activity (Fischer et
al., 2003), these results indicate that Trap230 functions
upstream of Fgf24 activation but downstream of Tbx5 during
limb development. Consistent with this proposal, wnt2b, which
functions upstream of Tbx5 (Ng et al., 2002), is expressed
normally in tpd mutants (Figs. 8A, E).
While Sox9 activity is important for development of the fin
cartilage elements, the initial induction, patterning and
outgrowth of pectoral fin buds is normal in Sox9a/Sox9b
double mutants (Yan et al., 2005), indicating that the tpd fin
phenotype cannot be attributed to loss of Sox9 activity, and that
Trap230 regulates a Sox9-independent mechanism in forelimb
development.
Discussion
The trapped mutation shares many phenotypes with Sox9
mutants
Although the Mediator complex functions as a general
coactivator for most pol II-driven transcription in eukaryotes, it
seems that different parts of Mediator regulate distinct sets of
genes by interacting with specific DNA-binding transcriptional
activators. In this study, we have shown that zebrafish Trap230
Fig. 7. Ear development in the absence of Trap230. (A, C, E, G) WT; (B, D, F, H) Trap230 MO-injected embryos. (A–D) Embryos at 3-somite stage, dorsal view,
anterior to the left. (E, F) Tailbud stage embryos, dorsal view, anterior to the left. (G, H) Lateral views of the ear at 24 hpf. (A, B) Sox9b expression in the otic placodes;
(C, D) Sox9b expression in the otic placodes. (E, F) pax8 expression in the otic placodes (arrows). (G, H) pax2.1 expression in the otic vesicle.
Fig. 8. The pectoral fin phenotype of tpdmutants. All embryos shown are 24 hpf, dorsal views, anterior to the top. (A–D, I–L) WT; (E–H, M–P) tpdmutant embryos.
(A, E) wnt2b expression. (B, F) tbx5.1 expression. (C, G) fgf24 expression. (D, H) msx-c expression. (I, M) dlx2a expression. (J, N) shh expression. (K, O) erm1
expression. (L, P) pea3 expression.
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zebrafish Trap230 mutant, and our characterization of this
mutant shows that it strongly resembles the Sox9a/Sox9b double
mutant in many different tissues.
The phenotypes shared between tpd and Sox9a/Sox9b
mutants include the complete absence of craniofacial
cartilages, the absence or strong reduction of otic placodes,
the absence of iridophores, the presence of expanded
melanophores and the presence of a curly-down body axis
and heart edema. The absence of craniofacial cartilages
correlates with strongly reduced col2a1 expression in this
region. col2a1 is a direct target of transcriptional activation by
Sox9 (Bell et al., 1997; Lefebvre et al., 1997; Ng et al., 1997;
Zhou et al., 1998) and is strongly reduced in Sox9a/Sox9b
mutants (Yan et al., 2005), therefore raising the possibility
that Trap230 functions as a transcriptional coactivator
participating in the regulation of Sox9 targets such as
col2a1. In regulating chondrogenesis, Sox9 has an important
interaction with beta-catenin (Akiyama et al., 2004), and it
will be interesting to determine whether Trap230 plays a role
in this interaction.
The absence of DRG neurons in tpd mutants has also been
described in mouse Sox9 mutants (Cheung et al., 2005), and
both zebrafish and mouse Sox9 mutants show elevated
apoptosis in pre- and post-migratory neural crest cells, similar
to tpd mutants.
Taken together, these results indicate that Trap230 is crucial
for Sox9 activity and is required for both Sox9a and Sox9b in
zebrafish, suggesting that the split of an ancestral Sox9 gene
into two teleost copies did not affect their interaction with
Trap230. Our results suggest that the interaction of Trap230
with Sox9 is relatively specific, since most tpd phenotypes can
be explained by disrupted Sox9 activity. However, Trap230
clearly also functions in Sox9-independent events, such as limb
induction and kidney development. It therefore remains to be
seen how many different vertebrate transcription factors
depend on Trap230. In the present study, we have focused
on the role of zygotically expressed Trap230, and it could be
that maternally expressed Trap230 is required for distinct
transcription factors.
The role of Trap230 in Sox9 activity
Since transcription of Sox9a and Sox9b is activated normally
in most tissues in the absence of Trap230 activity, this suggests
that Sox9 activity is disrupted in these mutants. Consistent with
this possibility, trap230 transcript is expressed ubiquitously
throughout the embryo, and Trap230 protein is therefore likely
to be present in the same cells as Sox9 protein, and the two
proteins could function together in the same gene regulatory
events. In further support of this proposal, injection of Sox9b
mRNA can trigger target gene activation in wild-type embryos
but not in tpd mutants.
These results are in strong agreement with the finding
that human SOX9 protein binds directly to TRAP230 in
vitro, both in a yeast two-hybrid assay, and in a GST pull-
down assay (Zhou et al., 2002). The PQL domain ofTRAP230 is both necessary and sufficient for this interaction
with the SOX9 transactivation domain. The PQL domain is
located near the C-terminus, which is deleted in both tpd
mutants and in Trap230 morphants, suggesting these
truncated forms are unable to bind Sox9. Our in vivo data
support this hypothesis, since substitution of the Sox9b
transactivation domain by a VP16 transactivation domain
abolishes the requirement of Sox9b for Trap230 activity.
This result also shows that Trap230 acts as a coactivator in
this context, which is in contrast to its role as a corepressor
in other contexts. In addition, our results show that Trap230
is required for Sox9 activity not only during chondrogenesis,
since other functions of Sox9 are also impaired in tpd
mutants.
Trap230 as a transcriptional coregulator during vertebrate
development
The Trap230/Med12 and Trap240/Med13 subunits are part
of a Mediator subcomplex that also contains Cdk8 and CycC
(reviewed in Björklund and Gustafsson, 2005; Malik and
Roeder, 2005). This module is variably present in the Mediator
complex, and its presence correlates with transcriptional
repression in yeast (Holstege et al., 1998; Samuelsen et al.,
2003; Spahr et al., 2003) and in mammalian cells (Naar et al.,
2002; Wang et al., 2001). These observations have led to a
model in which recruitment of Mediator containing this module
represses transcription, whereas Mediator devoid of this module
activates transcription. The role of this module may be more
complex, however, since Cdk8 is linked to the positive
regulatory effect of Mediator on pol II in Drosophila (Park et
al., 2001), and activation of the Notch signaling pathway leads
to the recruitment of Cdk8 and CycC to a Notch target promoter
(Fryer et al., 2004). Mediator containing this module may thus
be involved both in transcriptional activation and repression. In
C. elegans, Trap230 appears to be required for transcriptional
repression (Yoda et al., 2005), while in Drosophila it is not yet
clear if Trap230 participates in transcriptional repression or
activation (Janody et al., 2003).
Our results indicate that Trap230 is required for transcrip-
tional activation by Sox9. Thus, col2a1, a direct transcrip-
tional target of Sox9 activation (Bell et al., 1997; Lefebvre et
al., 1997; Ng et al., 1997; Zhou et al., 1998), shows strongly
reduced expression in tpd mutants. Furthermore, injection of
Sox9b mRNA can up-regulate foxd3, snai1b and Sox10
expression in wild type embryos but not in tpd mutant
embryos. In further support of the proposal that Trap230
functions as a coactivator for Sox9, replacement of the Sox9b
transactivation domain by a constitutive VP16 activation
domain leads to activation of snai1b by Sox9b independently
of Trap230 activity. This result is also consistent with the
observation that over-expression of a Trap230 fragment only
containing the Sox9-binding domain acts as a dominant
negative, blocking the ability of Sox9 to activate target gene
expression in vitro, thus suggesting that binding of full-length
Trap230 is crucial for transcriptional activation by Sox9
(Zhou et al., 2002).
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We have shown that tpd mutants fail to form pectoral fin
buds and lack all pectoral fin structures. Since Sox9 signaling is
not involved in the early steps of limb development, this is a
clear example of Trap230 involvement in a Sox9-independent
pathway. In addition, our data indicate that Trap230 is also
required for Sox9-independent kidney development, since pax8
expression in the pronephric anlage is strongly reduced in tpd
mutants.
Our results show that Trap230 functions upstream of Fgf24
during limb development, as fgf24 expression fails to be
activated in tpd mutants. Also, several genes that are activated
independently of Fgf24 in the limb bud mesenchyme, including
msx-c, erm1 and pea3 (Fischer et al., 2003), are strongly
reduced or absent in tpd embryos, thus further indicating that an
event upstream of Fgf24 is blocked in the absence of Trap230
activity.
Since tbx5 expression is activated in tpd mutants, our data
suggest that Trap230 is required for an event between Tbx5 and
Fgf24 activation. In the simplest scenario, Trap230 might bind
directly to Tbx5 and function as a coregulator, similar to its
interaction with Sox9. Alternatively, it could bind to a
transcription factor acting downstream of Tbx5. Future
experiments will help to distinguish between these possibilities.
The failure of tbx5-expressing cells to migrate towards the limb
bud is likely due to the absence of Fgf24, as the same effect is
observed in fgf24 mutants (Fischer et al., 2003).
In summary, we have shown that the zebrafish Trap230 gene,
a member of the Mediator complex, functions as a coactivator
necessary for activation of Sox9 target genes. In addition, it is
also required for several Sox9-independent events during
embryogenesis, including limb induction and kidney develop-
ment. It remains to be seen in which other regulatory events
during vertebrate development Trap230 participates.Acknowledgments
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